Malignant Mesothelioma

Malignant mesothelioma, or is often simply shortened to just mesothelioma, is a cancer of the mesothelium, the tissue that lines our lungs, stomach, heart and other organs. It is fairly rare, especially for people under age 55, however, a serious cancer.

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Also mesothelioma is very hard to control. Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient's age and general health. Standard treatment options include surgery, radiation therapy, and chemotherapy. Sometimes, these treatments are combined.

Working with asbestos is the major risk factor for mesothelioma. About 70 percent to 80 percent of all cases have been linked to asbestos exposure in the workplace. There is also some evidence that family members and others living with asbestos workers have an increased risk of developing mesothelioma, and possibly other asbestos-related diseases. This risk may be the result of exposure to asbestos dust brought home on the clothing and hair of asbestos workers.

If you got mesothelioma because of your workplace is "an asbestos environment," you can go to mesothelioma law firm and work together with the mesothelioma lawyer to make a claim. You need an experienced mesothelioma attorney not just an ordinary law firm or lawyer since it could mean the difference between success and failure.

CD4 Cell Count and AIDS-Defining Malignancies (ADM)

CD4 cell count is strongly associated with the risk of death from both AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM). Non-AIDS events have become an important cause of mortality as individuals with HIV infection survive to older ages and have started to suffer from similar age-related diseases to the HIV-uninfected population.
Rate of death of nADM is higher than from ADM in all patients other than those with very low CD4 cell counts. Lung cancer is the most common fatal nADM, concordance with the high prevalence of smoking among the HIV-infected population.
Age is also a strong predictor of death from malignancies, suggesting that, at similar CD4 cell counts, older patients are at greater risk of dying from malignancy. This may be a consequence of the higher incidence of cancers in older individuals, as well as an increased likelihood of death in older individuals, irrespective of the cause. However, this may also reflect reduced immune system activity in the elderly. Interestingly, the HIV RNA level was only weakly associated with ADM mortality and was not independently associated with nADM mortality.
Non-AIDS-defining malignancies was related to combination antiretroviral (cART) exposure. The individuals taking effective cART are less likely to die from ADM and, as a result, may be more likely to die from nADM. In contrast, patients dying from ADM may be more likely to have stopped or never received cART.
(AIDS. 2008;22(16):2143-2153)